The 'Learner-to-Patient Impact Framework' (touchLPI) advances our holistic approach to delivering impactful education that has a positive impact on patient health.

In this episode, Dr William (Bill) Damsky discusses JAK inhibitors' journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.

In this episode, we speak with Prof. John Mascarenhas, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.